Publications by authors named "Stuart Mealing"

Claim this Profile
P
Patterns of responses in time trade-off studies: a latent class analysis of health states worse than dead.
Adam B Smith, Stuart Mealing, Andria Joseph

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of the TriageHF Plus clinical pathway for device-based remote monitoring in heart failure.
Fozia Z Ahmed, Rachel Harwood, David Lanctin, Catherine Leonard, Sarah Medland, Stuart Mealing

Heart· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Economic and Clinical Impact of Recurring Automated Red Blood Cell Exchange to Manage Sickle Cell Disease in the UK.
Sarah M Medland, Jamie Bainbridge, Matthew Cawson, Stuart J Mealing, Anna Yudina

Pharmacoecon Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of RefluxStop compared to proton pump inhibitors and Nissen fundoplication for management of persistent gastroesophageal reflux disease in Norway.
Sam Harper, Muralikrishnan Kartha, Stuart Mealing, Lars Eftang, Robin Gaupset

Cost Eff Resour Alloc· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of a Digital Leakage Notification System (Heylo™) for People with Ileostomies or Colostomies in the United Kingdom.
Esben Bo Boisen, Matthew Cawson, Lasse de Fries Jensen, Stuart Mealing, Naomi van Hest

Pharmacoeconomics· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: an analysis based on the SECURE trial.
Thomas Gaziano, José María Castellano, Amy Dymond, Alissa Looby, Stuart Mealing

Lancet Reg Health Eur· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System.
Sam Harper, Muralikrishnan Kartha, Stuart Mealing, Maurizio Pavanello, Luigi Bonavina

Pharmacoecon Open· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective.
Malte Kuniss, Lucy Hillcoat, Joe Moss, Florian Straube, Jason Andrade, Stuart Mealing

BMC Health Serv Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical and economic impact of extended battery longevity of a substernal extravascular implantable cardioverter defibrillator.
Stuart Mealing, Emily Gregg, Charlotte Graham, Adam B Smith

J Cardiovasc Electrophysiol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden.
Sam Harper, Muralikrishnan Kartha, Stuart Mealing, Lars Lundell

Expert Rev Pharmacoecon Outcomes Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A danish healthcare-focused economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation.
Morten Lock Hansen, Joe W E Moss, Jacob Tønnesen, Mette Lundsby Johansen, Malte Kuniss, Stuart Mealing

BMC Cardiovasc Disord· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of the RefluxStop device for management of refractory gastroesophageal reflux disease in Switzerland.
Sam Harper, Muralikrishnan Kartha, Stuart Mealing, Yves M Borbély, Jörg Zehetner

J Med Econ· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Economic Evaluation of a Streamlined Day-Case Atrial Fibrillation Ablation Protocol and Conventional Cryoballoon Ablation versus Antiarrhythmic Drugs in a UK Paroxysmal Atrial Fibrillation Population.
Joe W E Moss, Derick Todd, Lukasz Grodzicki, Beatrice Palazzolo, Richard Mattock, Stuart Mealing

Pharmacoecon Open· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the Comparator in Your Diagnostic Cost-Effectiveness Model "Standard of Care"? Recommendations from Literature Reviews and Expert Interviews on How to Identify and Operationalize It.
Sara Graziadio, Emily Gregg, A Joy Allen, Paul Neveux, Brigitta U Monz, Stuart Mealing

Value Health· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost-Effectiveness of First-Line Cryoablation vs First-Line Antiarrhythmic Drugs in Canadian Patients With Paroxysmal Atrial Fibrillation.
Jason G Andrade, Joe W E Moss, Malte Kuniss, Hamid Sadri, Oussama Wazni, Stuart Mealing

Can J Cardiol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of a novel urethral catheter safety device in preventing catheterization injuries in the UK.
Stefanie M Croghan, Robert Malcolm, Hugh D Flood, Stuart Mealing, Brooke Avey

J Med Econ· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget Impact of RefluxStop™ as a Treatment for Patients with Refractory Gastro-oesophageal Reflux Disease in the United Kingdom.
Sam Harper, Lukasz Grodzicki, Stuart Mealing, Elizabeth Gemmill, Paul Goldsmith

J Health Econ Outcomes Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from an English National Health Service perspective.
John Paisey, Joe Moss, Jason Andrade, Malte Kuniss, Oussama Wazni, Stuart Mealing

Open Heart· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease.
Maria Mata Lorenzo, Mahmood Ali, Stuart Mealing, Joe Moss

J Med Econ· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Mikin V Patel, Heather Davies, Abimbola O Williams, Tom Bromilow, Hannah Baker, Stuart Mealing

J Med Econ· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An economic evaluation of first-line cryoballoon ablation vs antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a U.S. Medicare perspective.
Oussama Wazni, Joe Moss, Malte Kuniss, Jason Andrade, Gian Battista Chierchia, Stuart Mealing

Heart Rhythm O2· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
I-PreFer Study: A Discrete Choice Experiment to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Pharmacological Treatment Options.
Maria Hollmen, Marlies Wijsenbeek, Tom Bromilow, Adam B Smith, Stuart Mealing

Patient Prefer Adherence· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
I-PreFer Study: A Questionnaire to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Treatment Options.
Maria Hollmen, Tom Bromilow, Adam B Smith, Stuart Mealing, Damian Lewis

Patient Prefer Adherence· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of an antibacterial envelope for infection prevention in patients undergoing cardiac resynchronization therapy reoperations in Denmark.
Maria Hee Jung Park Frausing, Jens Brock Johansen, Daniela Afonso, Ole Dan Jørgensen, Thomas Olsen, Stuart Mealing

Europace· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease.
Sam Harper, Lukasz Grodzicki, Stuart Mealing, Liz Gemmill, Paul J Goldsmith

J Med Econ· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis